{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "28790194", "DateCompleted": {"Year": "2017", "Month": "10", "Day": "03"}, "DateRevised": {"Year": "2019", "Month": "01", "Day": "22"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2017", "Month": "08", "Day": "08"}], "ELocationID": ["10.1124/jpet.117.241794"], "Journal": {"ISSN": "1521-0103", "JournalIssue": {"Volume": "363", "Issue": "1", "PubDate": {"Year": "2017", "Month": "Oct"}}, "Title": "The Journal of pharmacology and experimental therapeutics", "ISOAbbreviation": "J Pharmacol Exp Ther"}, "ArticleTitle": "Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2<i>H</i>-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress.", "Pagination": {"StartPage": "114", "EndPage": "125", "MedlinePgn": "114-125"}, "Abstract": {"AbstractText": ["Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a key regulator of oxidative stress and cellular repair and can be activated through inhibition of its cytoplasmic repressor, Kelch-like ECH-associated protein 1 (Keap1). Several small molecule disrupters of the Nrf2-Keap1 complex have recently been tested and/or approved for human therapeutic use but lack either potency or selectivity. The main goal of our work was to develop a potent, selective activator of NRF2 as protection against oxidative stress. In human bronchial epithelial cells, our Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2<i>H</i>-chromen-2-one (PSTC), induced Nrf2 nuclear translocation, Nrf2-regulated gene expression, and downstream signaling events, including induction of NAD(P)H:quinone oxidoreductase 1 (NQO1) enzyme activity and heme oxygenase-1 protein expression, in an Nrf2-dependent manner. As a marker of subsequent functional activity, PSTC restored oxidant (<i>tert</i>-butyl hydroperoxide)-induced glutathione depletion. The compound's engagement of the Nrf2 signaling pathway translated to an in vivo setting, with induction of Nrf2-regulated gene expression and NQO1 enzyme activity, as well as restoration of oxidant (ozone)-induced glutathione depletion, occurring in the lungs of PSTC-treated rodents. Under disease conditions, PSTC engaged its target, inducing the expression of Nrf2-regulated genes in human bronchial epithelial cells derived from patients with chronic obstructive pulmonary disease, as well as in the lungs of cigarette smoke-exposed mice. Subsequent to the latter, a dose-dependent inhibition of cigarette smoke-induced pulmonary inflammation was observed. Finally, in contrast with bardoxolone methyl and sulforaphane, PSTC did not inhibit interleukin-1<i>\u03b2</i>-induced nuclear factor-<i>\u03ba</i>B translocation or insulin-induced S6 phosphorylation in human cells, emphasizing the on-target activity of this compound. In summary, we characterize a potent, selective Nrf2 activator that offers protection against pulmonary oxidative stress in several cellular and in vivo models."], "CopyrightInformation": "Copyright \u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Yonchuk", "ForeName": "John G", "Initials": "JG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Foley", "ForeName": "Joseph P", "Initials": "JP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Bolognese", "ForeName": "Brian J", "Initials": "BJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Logan", "ForeName": "Gregory", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Wixted", "ForeName": "William E", "Initials": "WE"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Kou", "ForeName": "Jen-Pyng", "Initials": "JP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Chalupowicz", "ForeName": "Diana G", "Initials": "DG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Feldser", "ForeName": "Heidi G", "Initials": "HG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Sanchez", "ForeName": "Yolanda", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Nie", "ForeName": "Hong", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Callahan", "ForeName": "James F", "Initials": "JF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania."}], "LastName": "Kerns", "ForeName": "Jeffrey K", "Initials": "JK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stress and Repair Discovery Performance Unit, Respiratory Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania patty.podolin@gsk.com."}], "LastName": "Podolin", "ForeName": "Patricia L", "Initials": "PL"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Pharmacol Exp Ther", "NlmUniqueID": "0376362", "ISSNLinking": "0022-3565"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2H-chromen-2-one"}, {"RegistryNumber": "0", "NameOfSubstance": "Coumarins"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-E2-Related Factor 2"}, {"RegistryNumber": "0", "NameOfSubstance": "NFE2L2 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Small Interfering"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfones"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "EC 1.6.5.2", "NameOfSubstance": "NAD(P)H Dehydrogenase (Quinone)"}, {"RegistryNumber": "GAN16C9B8O", "NameOfSubstance": "Glutathione"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Blotting, Western"}, {"QualifierName": [], "DescriptorName": "Cell Line"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cell Nucleus"}, {"QualifierName": ["administration & dosage", "blood", "therapeutic use"], "DescriptorName": "Coumarins"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Drug Discovery"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Epithelial Cells"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Expression"}, {"QualifierName": ["metabolism"], "DescriptorName": "Glutathione"}, {"QualifierName": [], "DescriptorName": "HEK293 Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Lung"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred C57BL"}, {"QualifierName": ["genetics"], "DescriptorName": "NAD(P)H Dehydrogenase (Quinone)"}, {"QualifierName": ["agonists", "genetics"], "DescriptorName": "NF-E2-Related Factor 2"}, {"QualifierName": ["drug effects"], "DescriptorName": "Oxidative Stress"}, {"QualifierName": ["toxicity"], "DescriptorName": "Ozone"}, {"QualifierName": ["etiology", "metabolism", "prevention & control"], "DescriptorName": "Pneumonia"}, {"QualifierName": [], "DescriptorName": "Protein Transport"}, {"QualifierName": ["metabolism"], "DescriptorName": "Pulmonary Disease, Chronic Obstructive"}, {"QualifierName": ["genetics"], "DescriptorName": "RNA, Small Interfering"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Smoking"}, {"QualifierName": ["administration & dosage", "blood", "therapeutic use"], "DescriptorName": "Sulfones"}, {"QualifierName": [], "DescriptorName": "Transfection"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2017", "Month": "5", "Day": "17"}, {"Year": "2017", "Month": "8", "Day": "2"}, {"Year": "2017", "Month": "8", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "10", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "8", "Day": "10", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["28790194", "10.1124/jpet.117.241794", "jpet.117.241794"]}}], "PubmedBookArticle": []}